The US Food and Drug Administration has agreed to expand the label of Dublin, Ireland-based Allergan’s Avycaz to include the treatment of complicated urinary tract infections (cUTI).
A late-stage study has confirmed the efficacy of AstraZeneca’s new combination antibiotic Zavicefta in patients with hospital acquired pneumonia (HAP), including ventilator associated pneumonia (VAP).
AstraZeneca’s Zavicefta has been approved for use in the European Union to treat patients with serious Gram-negative bacterial infections requiring hospitalisation.